Fulcrum Therapeutics

Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of Learn more about who we are at https://www.fulcrumtx.com/

Our approach to drug discovery generates significant insights into disease biology and allows us to think creatively about the best way to modulate and balance gene expression. Our initial areas of focus are facioscapulohumeral muscular dystrophy (FSHD), sickle cell disease (SCD) and beta thalassemia. We take great pride in being purposeful patient partners who do this work, not just for patients,

but with patients. We have a culture of trust and transparency which enables our employees to focus on our mission and the science behind it. In addition, we are invested in our people and want to ensure they have the tools and training they need to succeed. This allows our playful spirit to come alive, making work more enjoyable for our entire .

On Monday, June 1, Fulcrum Therapeutics announced the discontinuation of the pociredir program for the potential treatme...
06/05/2026

On Monday, June 1, Fulcrum Therapeutics announced the discontinuation of the pociredir program for the potential treatment of sickle cell disease (SCD).

We arrived at this difficult decision following discussions with the FDA and the conclusion that there was not a viable development path forward. This decision in no way diminishes our belief in the science or our profound respect for the SCD community.

We are beyond grateful for the SCD warriors, families, advocates, and broader community who walked alongside us, trusted us with their stories, participated in our clinical trials, advocated with policymakers, and shared their hopes for a better future. We are deeply saddened that this is the end of our journey when we know so much important work remains for the SCD community.

Read the full announcement on our website: https://ow.ly/oyrg50Z7P3r

05/29/2026

Individuals with sickle cell disease (SCD) face a higher risk of stroke. At our 2026 Bipartisan Congressional Briefing, Kyle Smith, of the Crescent Foundation: A Sickle Cell Initiative, shared his powerful story.

If you suspect someone is having a stroke, remember B.E. F.A.S.T.

Balance Loss
Eye (Vision) Changes
Face Drooping
Arm Weakness
Speech Difficulty
Time to call 911

During Mental Health Awareness Month, we recognize that health extends beyond physical symptoms, and that mental well-be...
05/20/2026

During Mental Health Awareness Month, we recognize that health extends beyond physical symptoms, and that mental well-being plays an important role for individuals living with SCD and caregivers alike.

Find mental health resources and support in the Sickle Cell Disease Association of America, Inc. I Believe in Therapy Toolkit: https://sicklecelldisease.org/mental-health-and-wellness/

04/23/2026

At Fulcrum, we believe community voices are central to the conversation, especially when the stakes are access, equity, and policies that affect the lived experiences of individuals with sickle cell.

Last month, our standing-room only Congressional Briefing was about elevating community voices, highlighting the many challenges faced by the SCD community, and our commitment to listen, learn, and take action.

Together, our voices pushed the conversation forward: the sickle cell community needs access to more options.

Missed the Congressional Briefing on Capitol Hill? Watch the full briefing here: https://ow.ly/GsxW50YOyyz

On and every day, we stand with the global sickle cell and blood disorder communities. At Fulcrum, we build meaningfu...
04/07/2026

On and every day, we stand with the global sickle cell and blood disorder communities.

At Fulcrum, we build meaningful connections to ensure individuals around the world have access to the science, research, and information shaping the future of sickle cell disease care. We are honored to engage the worldwide sickle cell community, including countries like Nigeria, Ireland, Jamaica, and more.

The room was full. The urgency was undeniable. And the message could not be ignored. Recently on Capitol Hill, Fulcrum h...
03/30/2026

The room was full. The urgency was undeniable. And the message could not be ignored. Recently on Capitol Hill, Fulcrum hosted a standing-room-only congressional briefing that brought together community voices to confront the reality of sickle cell disease in the U.S.

The message was clear: individuals living with sickle cell disease deserve better. More treatment options. Improved and timelier care. Policy action to ensure equitable access and continued innovation.

We’re deeply grateful to everyone who shared their stories, showed up, and moved this conversation forward, including congressional staff, patient advocates, clinicians, and policy leaders.

We are especially thankful to our partners, MedicAlert Foundation and Sickle Cell Disease Association of America, Inc., as we work together to address real barriers to sickle cell care in emergency situations with the MedicAlert Smart Medical ID Card.

At Fulcrum, we’re committed to partnering with the community to push past barriers and improve the whole journey, from innovation to access and beyond.

For the SCD patient community: tomorrow at 6 pm ET we’re hosting an important conversation about our science, progress, ...
03/29/2026

For the SCD patient community: tomorrow at 6 pm ET we’re hosting an important conversation about our science, progress, and research.

Your participation matters to us. Be part of the progress and stay informed about our investigational treatment Pociredir and the PIONEER Study.

It’s not too late to register here: https://ow.ly/Gmlo50YxUif

Join us next week for our patient community webinar on sickle cell disease (SCD)! Learn about ongoing research into a po...
03/24/2026

Join us next week for our patient community webinar on sickle cell disease (SCD)!

Learn about ongoing research into a potential new treatment and the PIONEER Study, which is exploring the safety, efficacy, and dosage of our investigational treatment Pociredir.

Your attendance is important to us. We look forward to seeing you there. Register at https://ow.ly/cAgQ50YxUfo

Power in Partnership: Together, MedicAlert Foundation, Sickle Cell Disease Association of America, Inc., and Fulcrum are...
03/19/2026

Power in Partnership: Together, MedicAlert Foundation, Sickle Cell Disease Association of America, Inc., and Fulcrum are breaking down barriers in emergency care for the sickle cell disease community.

MedicAlert and SCDAA established a program which provides rapid access to physician-approved care plans and critical health information – when people need it most – through a MedicAlert Smart Medical ID card. Fulcrum’s three-year commitment and support will ensure this program reaches even more individuals living with sickle cell disease.

Our commitment goes beyond research to drive progress in care and ensure individuals are heard, supported, and empowered every day AND in times of crisis.

Get your ID Card and read more about the program here: https://ow.ly/zLvZ50YwlNQ

We are honored to sponsor the Sick Cells’ 2026 Virtual Sickle Cell Disease (SCD) Policy Forum, where lived experience be...
03/17/2026

We are honored to sponsor the Sick Cells’ 2026 Virtual Sickle Cell Disease (SCD) Policy Forum, where lived experience becomes action. Sharing your journey with SCD is a powerful tool for change.

At Fulcrum, we recognize the importance of “Voices in Action” and stand with SCD advocates. Voices spark change, drive progress, and make meaningful differences for the community.

Register here: https://sickcells.org/policy-forum/

Address

26 Landsdowne Street
Cambridge, MA
02139

Website

Alerts

Be the first to know and let us send you an email when Fulcrum Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Fulcrum Therapeutics:

Shortcuts

Share

Category